ArticleOncotarget2017
The prognostic impact of overall treatment time on disease outcome in uterine cervical cancer patients treated primarily with concomitant chemoradiotherapy: a nationwide Taiwanese cohort study.
Article in Oncotarget, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Radiation therapy for gynecologic malignancies during the COVID-19 pandemic: International expert consensus recommendations.Gynecologic oncology · 2020Guideline
- Lobaplatin versus cisplatin in concurrent chemoradiotherapy for elderly cervical cancer: randomized controlled phase II study.Journal of gynecologic oncology · 2026Trial
- Centralization of MR image-guided adaptive brachytherapy for cervical cancer in Austria: feasibility and outcomes.Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al] · 2026Article
- Article
- Pace of Cervical Cancer Stage Progression Prior to Radiation Therapy Initiation, an Instrumental Variable Analysis.International journal of radiation oncology, biology, physics · 2026Article
- Article
- Is Moderately Hypofractionated Radiotherapy a Safe and Effective Strategy for Cervical Cancer?-A Review of Current Evidence.Current oncology (Toronto, Ont.) · 2026Review
- Exploration of Predictive Factors for Acute Radiotherapy-Induced Gastro-Intestinal Symptoms in Prostate Cancer Patients.Cancers · 2025Article
- Radiotherapy treatment time delay evidence, part I: Update on cervical, anal, prostate, and head and neck cancers.World journal of clinical oncology · 2025Review
- Fragmented Care and Guideline-Concordant Treatment in Locally Advanced Cervical Cancer.Obstetrics and gynecology · 2025Article
- The Impact of Split Radiation Therapy on the Management of Locally Advanced Cervical Cancer in Central Virginia.Cureus · 2025Article
- Prognostic Factors for Cervical Cancer in Asian Populations: A Scoping Review of Research From 2013 to 2023.Cureus · 2024Article
- Opportunities and challenges encountered in managing cervical cancer during the coronavirus disease 2019 pandemic.Infectious agents and cancer · 2024Review
- Moderated Hypofractionated Online Adaptive Radiotherapy in Locally Advanced Cervical Cancer: A Case Report.Cureus · 2024Article
- Investigating and Analyzing Prognostic Factors and Their Impact on Recurrent Cervical Cancers.Cureus · 2024Review
- Brachytherapy in gynecological malignancies at a tertiary care hospital: An analysis.Journal of contemporary brachytherapy · 2024Article
- Optimal cisplatin cycles in locally advanced cervical carcinoma patients treated with concurrent chemoradiotherapy.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2023Article
- Review
- Article
- Relative Efficiency of Radiation Treatment Centers: An Application of Data Envelopment Analysis.Healthcare (Basel, Switzerland) · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The importance of the overall treatment time (OTT) has a paradoxical status in the current era of concomitant chemoradiotherapy. The main objective of this nationwide study was to evaluate the correlation between overall treatment duration and clinical outcome in cervical cancer patients treated primarily with curative concurrent chemoradiotherapy (CCRT). In this population-based cohort study, 2,594 patients diagnosed with International Federation of Gynecology and Obstetrics (FIGO) stage I-IVA uterine cervical cancer were studied. Univariate and multivariate analyses of prognostic factors were analyzed using Cox's proportional hazards models. The median irradiation duration was 59 days. Significant prognostic factors related to poor cancer-specific survival (CSS) and overall survival (OS) included old age, non-squamous cell cancer type, high-grade histology, increased tumor size, advanced FIGO stage, and prolonged OTT. After multivariate analysis, prolonged treatment time remained as a significant factor for poor CSS (hazard ratio, HR = 1.33; p < 0.001) and OS (HR = 1.15; p = 0.05). Further subgroup analysis showed that the 5-year OS rates after a treatment time of ≤ 56 days compared with > 56 days in patients with FIGO stages I-IIB and III-IVA were 70% and 65% (p = 0.002) compared with 43% and 42% (p = 0.67), respectively. Inconclusion, completion of CCRT within 8 weeks is recommended, particularly for patients with FIGO stage I-IIB disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.